Thank you for your interest in participating in Qu Biologics’ Phase 1/2 clinical trial of QBECO Site Specific Immunomodulators (SSIs), an investigational treatment for Crohn’s disease.
Enrollment into this Phase 1/2 clinical trial has completed and we are no longer enrolling new participants. A summary of the trial results can be found here.
If you are interested in participating in our next clinical trial of QBECO SSI for the treatment of Crohn’s disease, which is expected to begin enrollment in 2017, you may sign up to receive updates.
We sincerely appreciate your interest in our novel investigational treatment for Crohn’s disease.